GeneDx Holdings Corp. files 10-Q

GeneDx Holdings Corp. reported a net loss of $63.3 million for the first quarter of 2026, a significant increase from the $6.5 million net loss in the same period of 2025, driven by a substantial impairment loss and increased operating expenses. The company's total revenue grew 17% year-over-year, primarily due to increased diagnostic test revenue, but it also took on new long-term debt.